Scientists ask: is the psychedelic 'Trip' necessary for Psilocybin's benefits?

NCT ID NCT06768944

First seen Jan 08, 2026 · Last updated Jun 19, 2026 · Updated 21 times

Summary

This study aims to find out if the intense, mind-altering experience caused by psilocybin (the active ingredient in magic mushrooms) is necessary for its positive after-effects. Healthy adult volunteers will receive psilocybin along with either a placebo or risperidone, a drug that can block the psychedelic experience. By comparing the two groups, researchers hope to understand whether the subjective 'trip' itself is key to any lasting benefits.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVESTIGATING THE IMPORTANCE OF THE SUBJECTIVE PSYCHEDELIC EXPERIENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Calgary

    RECRUITING

    Calgary, Alberta, T2N 4N1, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

Fractures, Stress

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.